Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study.
The effects of cisapride, a nondopaminolytic motility-enhancing agent, were studied in 56 patients with chronic functional dyspepsia; all had symptoms suggestive of delayed gastric emptying. The patients received 4 mg or 8 mg of cisapride or placebo orally three times daily for two successive three-week periods according to a randomized, double-blind, crossover study design. Although there was a high placebo response (55% showed good or excellent results), the global response to treatment was significantly (P = 0.024) in favor of cisapride (75% had good or excellent results). The drug was particularly superior to placebo (P = 0.03) in the improvement of a cluster of symptoms typical of postprandial discomfort, including early satiety and nausea. Side effects were minimal.
Deruyttere
M
M
Medical Center for General Practitioners, Heverlee, Belgium.
Lepoutre
L
L
Heylen
H
H
Samain
H
H
Pennoit
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D020117:Cisapride; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation
D010880:Piperidines; D020117:Cisapride